(AOF) – Genfit, a late-stage biopharmaceutical company committed to improving the lives of patients with rare and serious liver diseases, announces the publication of new data on the clinical performance of NIS2+ for detection in elderly patients , of risky non-alcoholic steatohepatitis (NASH), in Hepatology Communications.
In collaboration with Labcorp, a world leader in innovative laboratory services, the data described in the manuscript are the first to show and compare the clinical performance of NIS4 and its recently developed and improved version NIS2+, in a population of older adults ( ≥65 years), with those of well-established biomarker panels: FIB-4, NFS, ELF and ALT.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
